DE3787548T2
(de)
|
1986-03-12 |
1994-03-31 |
American Cyanamid Co |
Makrolid-Verbindungen.
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
EP0512042B1
(en)
|
1990-01-24 |
1998-04-08 |
BUCKLEY, Douglas I. |
Glp-1 analogs useful for diabetes treatment
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
WO1995033474A1
(fr)
|
1994-06-03 |
1995-12-14 |
Tsumura & Co. |
Composition medicinale
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
ES2237790T3
(es)
|
1996-11-12 |
2005-08-01 |
Novo Nordisk A/S |
Uso de peptidos glp-1.
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
AU2610699A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Derivatives of glp-1 analogs
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
EP1062240B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
AU2610599A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
EP1932535A3
(en)
|
1998-07-31 |
2008-10-29 |
Novo Nordisk A/S |
Stimulation of beta cell profileration
|
MY155270A
(en)
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
JP3702181B2
(ja)
|
1998-12-07 |
2005-10-05 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1の類似体
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
DE60038097T2
(de)
|
1999-02-22 |
2009-02-12 |
Merrion Research I Ltd. |
Feste orale dosierungsform enthaltend einen resorptionsverstärker
|
WO2000048589A1
(en)
|
1999-02-22 |
2000-08-24 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
NZ514916A
(en)
|
1999-04-30 |
2004-06-25 |
Amylin Pharmaceuticals Inc |
Exendins and exendin agonists linked to polyethylene glycol polymers
|
WO2000069911A1
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
GB9923436D0
(en)
|
1999-10-04 |
1999-12-08 |
American Home Prod |
Pharmaceutical compositions
|
US6793934B1
(en)
|
1999-12-08 |
2004-09-21 |
Shire Laboratories, Inc. |
Solid oral dosage form
|
US7049283B2
(en)
|
2000-12-06 |
2006-05-23 |
Novartis Ag |
Pharmaceutical compositions for the oral delivery of pharmacologically active agents
|
MXPA03005036A
(es)
|
2000-12-07 |
2003-09-05 |
Lilly Co Eli |
Proteinas de fusion glp-1.
|
WO2002048192A2
(en)
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
US20030068356A1
(en)
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
ATE408414T1
(de)
|
2001-07-31 |
2008-10-15 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
JP5196701B2
(ja)
|
2001-11-29 |
2013-05-15 |
エミスフィアー テクノロジーズ インコーポレイテッド |
クロモリンナトリウムの経口投与用製剤
|
JP2005526020A
(ja)
|
2002-02-01 |
2005-09-02 |
ファイザー・プロダクツ・インク |
アジスロマイシンの乾式造粒配合物
|
US20050148497A1
(en)
|
2002-02-20 |
2005-07-07 |
Khan Mohammed A. |
Method for administering glp-1 molecules
|
DE60327771D1
(de)
|
2002-07-04 |
2009-07-09 |
Zealand Pharma As |
Glp-1 und behandlungsmethode für diabetes
|
JP2004131398A
(ja)
|
2002-10-08 |
2004-04-30 |
Taihei Chemical Industrial Co Ltd |
錠剤用滑沢剤
|
US20050059605A1
(en)
|
2003-01-31 |
2005-03-17 |
Krishna Peri |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
PL1605897T3
(pl)
|
2003-03-19 |
2012-12-31 |
Lilly Co Eli |
Związki będące połączeniem GLP-1 z poli(glikolem etylenowym)
|
AU2004241242A1
(en)
|
2003-05-14 |
2004-12-02 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide YY and PYY agonists
|
US20070065505A1
(en)
|
2003-07-11 |
2007-03-22 |
Shoufeng Li |
Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
|
JP2007501812A
(ja)
|
2003-08-08 |
2007-02-01 |
ノボ ノルディスク アクティーゼルスカブ |
ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用
|
SI2932981T1
(sl)
|
2003-09-19 |
2021-11-30 |
Novo Nordisk A/S |
Albumin-vezavni derivati GLP-1
|
CA2550050A1
(en)
|
2003-12-18 |
2005-06-30 |
Novo Nordisk A/S |
Novel glp-1 analogues linked to albumin-like agents
|
DE602004026113D1
(de)
|
2003-12-18 |
2010-04-29 |
Novo Nordisk As |
Glp-1-verbindungen
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
WO2005099672A1
(en)
|
2004-04-13 |
2005-10-27 |
Ranbaxy Laboratories Limited |
A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
|
CN102040537A
(zh)
|
2004-05-06 |
2011-05-04 |
爱密斯菲尔科技公司 |
N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
|
RU2006138703A
(ru)
|
2004-05-06 |
2008-06-20 |
Эмисфире Текнолоджис |
Твердая лекарственная форма увлажненного гепарина
|
MXPA06013252A
(es)
|
2004-05-14 |
2007-02-28 |
Emisphere Tech Inc |
Compuestos y composiciones para suministrar agentes activos.
|
WO2005121090A1
(en)
|
2004-06-02 |
2005-12-22 |
Abbott Laboratories |
Substituted piperidines that have antiangiogenic activity
|
CN101010339B
(zh)
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
KR20070029247A
(ko)
|
2004-07-08 |
2007-03-13 |
노보 노르디스크 에이/에스 |
폴리펩티드 연장 태그
|
JP2008509933A
(ja)
|
2004-08-13 |
2008-04-03 |
エミスフェアー・テクノロジーズ・インク |
送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
|
EP1799710A2
(en)
|
2004-10-07 |
2007-06-27 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
EP1843755B1
(en)
|
2005-02-01 |
2015-04-01 |
Emisphere Technologies, Inc. |
Gastric retention and controlled release delivery system
|
WO2006082204A1
(en)
|
2005-02-02 |
2006-08-10 |
Novo Nordisk A/S |
Insulin derivatives
|
WO2006096515A2
(en)
|
2005-03-04 |
2006-09-14 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
EP1863521B1
(en)
|
2005-03-18 |
2014-05-07 |
Novo Nordisk A/S |
Extended glp-1 compounds
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
EP1863537A2
(en)
|
2005-03-18 |
2007-12-12 |
Novo Nordisk A/S |
Dimeric peptide agonists of the glp-1 receptor
|
US20080260818A1
(en)
|
2005-03-28 |
2008-10-23 |
Dexcel Pharma Technologies Ltd. |
Controlled Absorption of Statins in the Intestine
|
KR20080026117A
(ko)
|
2005-05-26 |
2008-03-24 |
브리스톨-마이어스 스큅 컴퍼니 |
N-말단 개질된 glp-1 수용체 조절제
|
NZ566763A
(en)
|
2005-08-19 |
2011-06-30 |
Amylin Pharmaceuticals Inc |
Exendin-4 for treating diabetes, obesity and reducing body weight
|
US20070049557A1
(en)
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
WO2007061434A2
(en)
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
CN101309674A
(zh)
|
2005-11-17 |
2008-11-19 |
诺瓦提斯公司 |
药物组合物
|
WO2007067964A2
(en)
|
2005-12-08 |
2007-06-14 |
Nastech Pharmaceutical Company Inc. |
Mucosal delivery of stabilized formulations of exendin
|
CN105232482A
(zh)
|
2006-04-07 |
2016-01-13 |
默里昂研究Iii有限公司 |
包含增强剂的固体口服剂型
|
US8927015B2
(en)
|
2006-04-12 |
2015-01-06 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
ES2548393T3
(es)
|
2006-05-09 |
2015-10-16 |
Novo Nordisk A/S |
Derivado de insulina
|
CA2654566A1
(en)
|
2006-06-09 |
2007-12-21 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
US9364502B2
(en)
|
2006-06-28 |
2016-06-14 |
Emisphere Technologies, Inc. |
Gallium nitrate formulations
|
US20080014813A1
(en)
|
2006-07-12 |
2008-01-17 |
Building Materials Investment Corporation |
Fiber mat with formaldehyde-free binder
|
ES2296529B1
(es)
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
Composicion farmaceutica con promotores de absorcion.
|
CA2662080C
(en)
|
2006-09-07 |
2012-07-17 |
F. Hoffmann-La Roche Ag |
A process for the manufacture of snac (salcaprozate sodium)
|
JO2945B1
(en)
|
2006-09-13 |
2016-03-15 |
سميث كلاين بيتشام كوربوريشن |
Methods of giving prolonged hypoglycemic agents
|
WO2008039351A2
(en)
|
2006-09-22 |
2008-04-03 |
Novartis Ag |
Method of manufacturing tablets containing pharmacologically active agents
|
WO2008070543A1
(en)
|
2006-12-01 |
2008-06-12 |
Emisphere Technologies Inc. |
Improved acyclovir formulations
|
AU2008223108B2
(en)
|
2007-03-02 |
2013-10-10 |
Novartis Ag |
Oral administration of a calcitonin
|
EP2171080A4
(en)
|
2007-06-12 |
2010-10-27 |
Glaxosmithkline Llc |
METHODS OF PROTEIN DETECTION IN PLASMA
|
WO2009032749A2
(en)
|
2007-08-29 |
2009-03-12 |
The Regents Of The University Of Californina |
Salicylanilide modified peptides for use as oral therapeutics
|
EP2190460B1
(en)
|
2007-09-05 |
2014-12-17 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
EP2190872B1
(en)
|
2007-09-05 |
2018-03-14 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
CN101842386A
(zh)
|
2007-09-05 |
2010-09-22 |
诺沃-诺迪斯克有限公司 |
截短的glp-1衍生物和它们的治疗用途
|
MX2010003979A
(es)
|
2007-10-16 |
2010-06-02 |
Biocon Ltd |
Composicion farmaceutica oralmente administrable y proceso para su preparacion.
|
AU2008318423B2
(en)
|
2007-11-02 |
2013-12-05 |
Emisphere Technologies, Inc. |
Method of treating vitamin B12 deficiency
|
US20090124639A1
(en)
|
2007-11-06 |
2009-05-14 |
Emisphere Technologies Inc. |
valacyclovir formulations
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
ES2823233T3
(es)
|
2008-08-18 |
2021-05-06 |
Entera Bio Ltd |
Métodos y composiciones para la administración oral de proteínas
|
US8637647B2
(en)
|
2008-09-12 |
2014-01-28 |
Novo Nordisk A/S |
Method of acylating a peptide or protein
|
US8865759B2
(en)
|
2008-10-15 |
2014-10-21 |
Bayer Intellectual Property Gmbh |
Use of dithiine-tetracarboximides for controlling phytopathogenic fungi
|
CN101463081B
(zh)
|
2009-01-12 |
2012-07-04 |
华东师范大学 |
一种glp-1衍生物
|
BRPI1013639A2
(pt)
|
2009-02-13 |
2016-04-19 |
Boehringer Ingelheim Int |
medicamentos antidiabéticos
|
AR077956A1
(es)
|
2009-09-14 |
2011-10-05 |
Bayer Cropscience Ag |
Combinaciones de compuestos activos
|
CA2784120A1
(en)
|
2009-12-16 |
2011-07-14 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
MX2012006634A
(es)
|
2009-12-16 |
2012-06-21 |
Novo Nordisk As |
Derivados de peptidos tipo glucagon 1 de doble acilato.
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
WO2011109787A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Methods of administering insulinotropic peptides
|
GB2478849A
(en)
|
2010-03-16 |
2011-09-21 |
Chiasma Inc |
Improved pharmecutical compositions and methods of delivery
|
BR112012027893A2
(pt)
|
2010-04-30 |
2019-09-24 |
Sanwa Kagaku Kenkyusho Ltd |
peptídeo para aumento da bioestabilidade de substância bioativa e substância biotiva que possui bioestabilidade aumentada.
|
JP6034781B2
(ja)
|
2010-05-05 |
2016-11-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
併用療法
|
DE202010015867U1
(de)
|
2010-11-25 |
2011-05-05 |
Buchhalter, Thomas |
Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
|
SI2651398T1
(en)
|
2010-12-16 |
2018-04-30 |
Novo Nordisk A/S |
SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
|
AU2012241894B2
(en)
|
2011-04-12 |
2015-12-03 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
JP6006309B2
(ja)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals,Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
EP3542790B1
(en)
|
2012-03-22 |
2023-09-13 |
Novo Nordisk A/S |
Compositions comprising a delivery agent and preparation thereof
|
ES2690553T3
(es)
|
2012-03-22 |
2018-11-21 |
Novo Nordisk A/S |
Composiciones de péptidos GLP-1 y preparación de estas
|
US9993430B2
(en)
|
2012-06-20 |
2018-06-12 |
Novo Nordisk A/S |
Tablet formulation comprising semaglutide and a delivery agent
|
PT2991671T
(pt)
|
2013-05-02 |
2018-11-05 |
Novo Nordisk As |
Dosagem oral de compostos de glp-1
|
JP6925970B2
(ja)
|
2015-02-09 |
2021-08-25 |
エンテラ バイオ エルティーディー. |
副甲状腺機能低下症の治療
|
AU2016335287A1
(en)
|
2015-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|